Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension

by | Oct 28, 2025 | Clinical Trials | 0 comments

​ Conditions: HFrEF – Heart Failure With Reduced Ejection Fraction; HFpEF – Heart Failure With Preserved Ejection Fraction; Group 2 Pulmonary Hypertension

Interventions: Drug: JK07

Sponsors: Salubris Biotherapeutics Inc

Not yet recruiting Conditions: HFrEF – Heart Failure With Reduced Ejection Fraction; HFpEF – Heart Failure With Preserved Ejection Fraction; Group 2 Pulmonary Hypertension
Interventions: Drug: JK07
Sponsors: Salubris Biotherapeutics Inc
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *